You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,592,226

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,592,226

Title:	Solenopsin and derivatives, therapeutic compositions; and methods related thereto
Abstract:	This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula: ##STR00001## or salts, esters or prodrugs thereof as described herein.
Inventor(s):	Arbiser; Jack L. (Atlanta, GA), Bowen; J. Philip (Atlanta, GA), Watkins; E. Blake (Jackson, TN)
Assignee:	Emory University (Atlanta, GA) Mercer University (Atlanta, GA) Union University (Jackson, TN)
Application Number:	14/794,094
Patent Claims:	1. A pharmaceutical composition in a form selected from a tablet, capsule, and pill comprising 1-(piperidin-2-yl)decan-1-ol or salt thereof and a pharmaceutically acceptable excipient. 2. A method of treating leukemia comprising administering an effective amount of pharmaceutical composition comprising 1-(piperidin-2-yl)decan-1-ol or salt thereof to a subject in need thereof. 3. The method of claim 2, wherein the leukemia is selected from acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia, and acute monocytic leukemia (AMOL). 4. The method of claim 2 wherein the compound is administered in combination with a second anti-cancer agent. 5. The method of claim 4, wherein the second anti-cancer agent is gefitinib, erlotinib, docetaxel, cis-platin, 5-fluorouracil, gemcitabine, tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin, vincristine, vinblastine, vindesine, vinorelbine taxol, taxotere, etoposide, teniposide, amsacrine, topotecan, camptothecin, bortezomib, anagrelide, tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene, fulvestrant, bicalutamide, flutamide, nilutamide, cyproterone, goserelin, leuprorelin, buserelin, megestrol, anastrozole, letrozole, vorazole, exemestane, finasteride, marimastat, trastuzumab, cetuximab, dasatinib, imatinib, bevacizumab, combretastatin, thalidomide, and/or lenalidomide or combinations thereof. 6. A method of treating melanoma or skin cancer comprising administering an effective amount of pharmaceutical composition comprising 1-(piperidin-2-yl)decan-1-ol of salt thereof to a subject in need thereof. 7. The method of claim 6, wherein the subject diagnosed with, exhibiting symptoms of, or at risk of actinic keratosis, psoriasis, squamous cell carcinoma or basal cell carcinoma. 8. The method of claim 6 wherein the compound is administered in combination with a second anti-cancer agent. 9. The method of claim 8, wherein the second anti-cancer agent is gefitinib, erlotinib, docetaxel, cis-platin, 5-fluorouracil, gemcitabine, tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin, vincristine, vinblastine, vindesine, vinorelbine taxol, taxotere, etoposide, teniposide, amsacrine, topotecan, camptothecin, bortezomib, anagrelide, tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene, fulvestrant, bicalutamide, flutamide, nilutamide, cyproterone, goserelin, leuprorelin, buserelin, megestrol, anastrozole, letrozole, vorazole, exemestane, finasteride, marimastat, trastuzumab, cetuximab, dasatinib, imatinib, bevacizumab, combretastatin, thalidomide, and/or lenalidomide or combinations thereof.

Details for Patent 9,592,226

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2033-05-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2033-05-07
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2033-05-07
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2033-05-07
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2033-05-07
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2033-05-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.